NCT07526974
A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat ( SUPREME-02 )
StatusRecruiting
PhasePhase 3
Primary completion (estimated)
At risk: Primary endpoint(s) modified.
See at-risk trials from Caliway Biopharmaceuticals Co., Ltd.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Recruitment opened Show 5 more changesShow less
- Primary endpoint(s) modified
- Eligibility criteria expanded, about 24 words
- Start date changed from estimate of Oct 2026 to Nov 9, 2026
- Study sites: 14 to 15
- Study description shortened, about 1 word
- Notable Eligibility criteria expanded, about 26 words
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Percentage of participants achieving at least a 2-grade improvement on Patient Reported-Abdominal Fat Rating Scale (PR-AFRS) and Clinician Reported Abdominal Fat Rating Scale (CR-AFRS) in the CBL-514 group versus the placebo group.
Timeframe: From baseline to 4 weeks after final treatment
Secondary (2)
Percentage change from baseline in abdominal fat in the CBL-514 group versus the placebo group.
Percentage of participants with at least a 1-grade improvement on both Participant Reported Abdominal Fat Rating Scale (PR-AFRS) and Clinician Reported Abdominal Fat Rating Scale (CR-AFRS) in the CBL-514 group versus the placebo group.
Arms and interventions
CBL-514 injectionExperimental
Participants will receive CBL-514 administered up to 120 mL per treatment at a 4-weeks interval for up to 4 treatments.
Injectable 0.9% Sodium Chloride solutionPlacebo comparator
Participants will receive 0.9% Sodium Chloride administered up to 120 mL per treatment at a 4-week interval for up to 4 treatments.
Drugs: CBL-514 Injection, 0.9% Sodium Chloride
Sites
15 sites in 2 countries
United States 13, Canada 2